ABL Bio Completes Patent Registration for Immuno-Oncology Drug ABL503 in Chile and South Africa

ABL Bio announced on the 5th that it has completed patent registration for its immuno-oncology drug 'ABL503' in Chile and the Republic of South Africa.

ABL Bio CI. [Image provided by ABL Bio]

These patents secure rights until 2039. In addition, examinations for patent registration are underway in more than 20 countries, including the United States, China, Europe, and Japan.

ABL Bio's ABL503 is a bispecific antibody pipeline targeting both PD-L1 and 4-1BB simultaneously, co-developed with Nasdaq-listed company I-Mab.

While the blockbuster new drug Keytruda, based on PD-(L)1 mechanism, can be broadly applied to more than 20 cancer types, it has the limitation of being effective in only 20% of all patients. Developed to overcome the limitations of PD-(L)1-based immuno-oncology drugs, ABL503 is a bispecific antibody that combines a PD-L1 targeting antibody with a 4-1BB targeting antibody, designed to enhance immune cell activation and add memory T cell function, thereby demonstrating improved efficacy. ABL503 is currently undergoing Phase 1 clinical trials in the United States and Korea.

Lee Sang-hoon, CEO of ABL Bio, stated, "For pure research and development (R&D)-based biotech companies like ABL Bio, protection of intellectual property rights, including patents, is as important as the research and development of new drugs." He added, "Not only ABL503 but also other pipelines in clinical progress are proving their value through data, and patent registrations are actively being pursued."

The CEO explained, "Patent registrations in various countries will create more opportunities and flexibility in establishing clinical and commercialization strategies for future new drug pipelines."

This content was produced with the assistance of AI translation services.